Relief of the Crabtree effect by arsenate.
D000818:Animals; D001151:Arsenic / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D002286:Carcinoma, Ehrlich Tumor / Q000378:metabolism*; D005947:Glucose / Q000494:pharmacology*; D066298:In Vitro Techniques; D008928:Mitochondria / Q000187:drug effects; D009840:Oligomycins / Q000494:pharmacology; D010085:Oxidative Phosphorylation / Q000187:drug effects; D010101:Oxygen Consumption / Q000187:drug effects*; D010710:Phosphates / Q000494:pharmacology; D014475:Uncoupling Agents / Q000494:pharmacology
D009840:Oligomycins; D010710:Phosphates; D014475:Uncoupling Agents; D005947:Glucose; D001151:Arsenic